Access HIV Ag/Ab Combo Assay - European Union (EU) Clinical Trial Protocol

HIV I Infection Clinical Trial

— HIV-EU-11-18  

Official title:

Evaluation of the Beckman Coulter Access HIV Ag/Ab Combo Assay as an Aid in the Diagnosis of HIV-1 and/or HIV-2 Infection: EU Clinical Trial Protocol

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04971343
• Other study ID #: DC-TR18-0410
• Status: Completed
• Start date: December 4, 2019
• Est. completion date: September 23, 2022

Study information

• Verified date: October 2022
• Source: Beckman Coulter, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The objective of this study is the collection and testing of clinical samples to determine the clinical performance of the Access HIV Ag/Ab Combo assay on the DxI 9000 Access Immunoassay Analyzer

Description:

The study will involve a multicenter, prospective and retrospective sample collection, and testing of samples with the investigational HIV assay as required per the EU Common Technical Specification (CTS). The CTS requires testing of samples from blood donors, hospitalized patients, known HIV-1 Ab positive patients, known HIV-2 Ab positive patients, and known HIV-1 p24 Ag positive patients. Any retrospectively collected samples will meet all inclusion/exclusion criteria.

All samples collected will be anonymized or pseudo-anonymized, leftover, remnant samples. pseudo-anonymized collection of samples will required oral patient consent documented in their medical record or electronic case report form (eCRF). For CE marking, below is the number of samples that will be included per group :

• Unselected blood donors : 6,000 fresh samples (requirements CTS : 5,000)

• Hospitalized patients : 1,200 frozen samples and 800 fresh samples (requirements CTS :

200)

• Known HIV-1 Ab positive : 470 frozen samples and 30 fresh samples (requirements CTS :

400)

• Known HIV-2 Ab positive : 100 frozen samples (requirements CTS : 100)

• Known acute HIV-1 p24 Ag positive : 50 frozen samples (requirements CTS : 50)

The following additional design requirements will be incorporated to EU study to satisfy Canadian regulations, but additional data generated on the additional samples will not be used for CE-marking:

• Collection and testing of 4,000 additional blood donor samples. Blood donors' samples should include 300 blood donor matched fresh plasma and serum samples

• Distribution of blood donor sample testing equally over three (3) blood donor sites, using 3 different lots of reagents

• Retesting of 1000 blood donor samples internally with 1 lot close to expiration

• Collection and testing of maximum 210 additional p24 Ag positive sample beyond the 50 required by CTS

• Distribution of p24 Ag and HIV-1 Ab positive sample testing equally over three (3) testing sites, using 3 different lots of reagents.

Additional Canadian requirements will be covered by US protocol(s) and Verification and validation protocols.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 8650
• Est. completion date: September 23, 2022
• Est. primary completion date: June 22, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Anonymized or pseudo-anonymized leftover samples from

• Males or females

• Aged =18 years of age

• Belonging to one of the following enrollment groups:

• Unselected blood donor

• Hospitalized patient

• Known HIV-1 antibody positive patients

• confirmed positive by Immunoblot, Western blot or HIV-1/HIV-2 antibody differentiation test either at time of enrollment vai same study draw or historically from medical record

• Known HIV-2 antibody positive patients

• confirmed HIV-2 positive by BioPlex 2200 HIV Ag-Ab Assay

• Known HIV-1 Ag positive patients

• For samples from HIV seroconversion panels

• Tested during EU HIV clinical trial: confirmed positive by screening HIV Ag/Ab combo positive for p24 Ag, and p24 Ag screening test positive (result from CoA or additional testing)

• Tested as part of seroconversion panel studies (V&V studies): First sample of the panel that is ARCHITECT Ag/Ab combo assay positive or BioPlex 2200 HIV Ag-Ab Assay p24 positive, and p24 Ag test positive (result from CoA or additional R&D testing)

• For routine clinical samples:

• Confirmed positive by screening HIV Ag/Ab combo assay positive for p24 Ag , and p24 Ag test positive by confirmatory test, or

• Confirmed positive by screening HIV Ag/Ab combo assay HIV positive, and p24 Ag test positive by confirmatory test and PCR HIV POS and IB/WB HIV negative or indetermined.

• with at least 2.0 mL leftover EDTA plasma sample from hospitalized patients OR

• at least 1.5 mL leftover EDTA plasma or serum sample from blood donors or known HIV-1 antibody positive patients, with confirmatory test already done as per inclusion criteria OR

• at least 1.0 mL leftover EDTA plasma or serum sample from known p24 Ag positive patients or known HIV-2 antibody positive patients, with confirmatory test already done as per inclusion criteria

Exclusion Criteria:

• Samples from subjects already included in the study

Related Conditions & MeSH terms

• Communicable Diseases
• HIV I Infection
• HIV-2 Infection
• Infections

Intervention

Diagnostic Test:
• Access HIV_blood donor
Samples will be tested with both reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFU to determine non-reactive, initially reactive, and repeatedly reactive. Reference assay will be Roche - Cobas - Elecsys® HIV Duo . All initially reactive specimen results will be tested in duplicate per IFU . All RR specimens will be confirmed using testing including ImmunoBlot, Western Blot or HIV-1/HIV-2 differentiation test and HIV-1 PCR, RNA (if Immunoblot, WesternBlot or differentiation test is negative or indeterminate; if Immunoblot, WesternBlot or differentiation test is positive for HIV-2 then HIV-1 PCR will not be tested).
• Access HIV_Hospitalized patient
All samples will be tested with both reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFU to determine non-reactive, initially reactive, and repeatedly reactive. Reference assay will be Abbott Architect HIV Ag/Ab combo assay for hospitalized patient. All initially reactive specimen results will be tested in duplicate per IFU . All RR specimens will be confirmed using testing including ImmunoBlot, Western Blot or HIV-1/HIV-2 differentiation test and HIV-1 PCR, RNA (if Immunoblot, WesternBlot or differentiation test is negative or indeterminate; if Immunoblot, WesternBlot or differentiation test is positive for HIV-2 then HIV-1 PCR will not be tested).
• Access HIV_known HIV-1 antibody positives
Samples will be tested with both reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFU to determine non-reactive, initially reactive, and repeatedly reactive. Reference assay will be Abbott Architect HIV Ag/Ab combo assay . All initially reactive specimen results will be tested in duplicate per IFU . For the known positive cohorts (sensitivity cohorts), samples will be identified as positive at enrollment/time of testing according to inclusion criteria prior to testing or in parallel of testing with Access and Reference HIV Ag/Ab combo assays. In case of discrepant results or concordant negative results between Access and Reference HIV Ag/Ab combo assay among known HIV-1 antibody positive patients, the IB/WB test will be repeated by the site to confirm sample status. If this IB/WB result is negative or indeterminate, the sample will be excluded from the statistical analysis
• Access HIV_known HIV-2 antibody positives
Samples will be tested with both reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFU to determine non-reactive, initially reactive, and repeatedly reactive. Reference assay will be Abbott Architect HIV Ag/Ab combo assay. All initially reactive specimen results will be tested in duplicate per IFU . For the known positive cohorts (sensitivity cohorts), samples will be identified as positive at enrollment/time of testing according to inclusion criteria prior to testing or in parallel of testing with Access and Reference HIV Ag/Ab combo assays.
• Access HIV_known HIV-1 p24 Ag positive
All samples will be tested with both Reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFUs/study guide to determine non-reactive (NR), initially reactive (IR), and repeatedly reactive (RR). Reference assay will be Abbott - ARCHITECT HIV Ag/Ab Combo Assay. Due to volume constraints, all known HIV-1 p24 Ag positive samples that will be tested during the EU HIV clinical trial will be tested in singulare only with the Reference HIV Ag/Ab combo assay, and in singulare and then in duplicate if IR with Access HIV Ag/Ab combo assay. For the known positive cohorts (sensitivity cohorts), samples will be identified as positive at enrollment/time of testing according to inclusion criteria prior to testing or in parallel of testing with Access and Reference HIV Ag/Ab combo assays
• Access HIV_Canada's requirements_Blood donor
To fit with Canada's requirements: 4,000 additional blood donor samples from geographically distinct regions will be collected and tested. Blood donor sample testing will be equally distributed over three blood donor sites, using 3 different lots of reagents: the first 2,000 blood donor samples from CE-marking study (out of the 6,000 tested) will be used plus the 4,000 additional blood donor samples. Retesting of 1000 blood donor samples will be done internally with 1 lot close to expiration to satisfy Canadian requirements
• Access HIV_Canada's requirements_HIV positive
To fit with Canada's requirements: o HIV positive samples will be equally distributed and tested at leat three (3) testing sites, using 3 lots of reagents.
• Access HIV_Canada's requirements_P24 Positive
To fit with Canada's requirements: HIV positive samples will be equally distributed and tested at leat three (3) testing sites, using 3 lots of reagents. Collection and testing of maximum 210 additional HIV-1 Ag positive sample beyond the 50 required by CTS

Locations

Country	Name	City	State
France	Etablissement Français du Sang (EFS) Hauts-de-France - Normandie	Bois-Guillaume
France	Eurofins Biomnis	Ivry-sur-Seine
France	UPR Lille, Établissement français du sang Hauts-de-France - Normandie	Loos
France	Laboratoire de Virologie, Laboratoire associé au CNR du VIH	Rouen
France	Cerba Xpert	Saint-Ouen-l'Aumône

Sponsors (1)

Lead Sponsor	Collaborator
Beckman Coulter, Inc.

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sensitivity and specificity	Sensitivity and specificity relative to the final patient HIV infection status determined from confirmatory testing will be calculated.	Baseline